

Follicular LymphomaChronic Lymphocytic Leukemia

Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia

Trial Status
Completed

Trial Runs In
1 Country

Trial Identifier
NCT03374137 ML30074

The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

Official Title:

Post-Marketing Surveillance of Gazyva in Treatment of Patients With Gazyva in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Patients

Trial Summary:

This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT03374137 ML30074
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
18 Years

Healthy Volunteers
No

Inclusion Criteria:

- Administered obinutuzumab under the approved indications in Korea at investigator's discretion
- Previously untreated with obinutuzumab

ForPatients

by Roche

Exclusion Criteria:

- Out-of locally approved indications, dosage, and administration
- Pregnant women, breastfeeding women
- Hepatic disease
- Participate in other clinical trials